Hubei Jumpcan Pharmaceutical Co Ltd (600566.SS)
12 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2017||Chairman of the Board, General Manager|
|39||2017||Chief Financial Officer, Secretary of the Board|
|64||1997||Chief Accounting Officer, Director|
|49||2003||Deputy General Manager|
|50||1997||Deputy General Manager|
- BRIEF-Hubei Jumpcan Pharmaceutical issues 843.2 mln yuan convertible corporate bonds
- BRIEF-Hubei Jumpcan Pharmaceutical to issue 843.2 mln yuan convertible bonds
- BRIEF-Hubei Jumpcan Ppharmaceutical's 9-month net profit up 34.2 pct y/y
- BRIEF-Hubei Jumpcan Pharma gets regulatory approval to issue bonds
- BRIEF-Hubei Jumpcan Pharmaceutical gets regulatory approval to issue convertible bonds